2A Pharma https://validator.w3.org/feed/docs/rss2.html 2AP01: AAVLP-HPV 2A Pharma is attending the 23rd World Vaccine Congress Europe Contact Poster preliminary proof-of-concept studies Temp – Team News Pipeline Clinical trials explained Jeanette presents E-poster at IPVC 2021 Home Scientific Foundation Jeanette Prangsgaard speaks about clinical trials 2016 Hope for Alzheimer’s’ 2A Pharma celebrates its 5th anniversary 2018 Temp – TL 2019 2020 2017 2017 2018 About Investors 2AP07: AAVLP-EpCAM+ STONY Brook University (Ebola & Coronavirus) GNL, Galveston National Laboratory in Texas (Ebola & Coronavirus) DTI, Danish Technology Institute DNASense John’s Hopkins University Medigene AAU, Aalborg University Peter Lainevool, Chairman John Nieland Preben Bruun-Nyzell John Nieland Preben Bruun-Nyzell Emma Huus Nicole Overmars 2A Pharma is a reality First financing round closed Exclusive worldwide license agreement Article about 2A Pharma in MedWatch Press release: 2A Pharma AB raises SEK 27 million and signs exclusive worldwide license agreement BIO Europe Spring 2018 2A Pharma secures SEK 20 million of funding See our presentation at BIO Europe 2018 on Tuesday, 6 November at 4.30pm Eurostars funding for therapeutic head and neck cancer vaccine project 2A Pharma receives approval for phase 1 study of 2AP01 Article in MedWatch